Сывороточный кальпротектин в роли маркера активации аутоиммунитета при ревматических заболеваниях

Кальпротектин – гетеродимер, образованный двумя белками, S100A8 и S100A9, которые в основном продуцируются активированными моноцитами и нейтрофилами. Роль кальпротектина в патогенезе, диагностике и мониторинге ревматических заболеваний привлекает большое внимание в последние годы. Согласно современным данным, циркулирующий сывороточный кальпротектин может рассматриваться в качестве маркера воспалительного процесса, обусловленного активностью нейтрофилов. Обнаружена связь между его высоким уровнем с некоторыми тяжелыми проявлениями аутоиммунных заболеваний, например, такими как гломерулонефрит, фиброз легких. Также представляет интерес его потенциальная роль мишени для лекарственной терапии, индикатора прогноза терапевтического ответа на лечение. В данной статье рассмотрены ключевые биологические функции кальпротектина, которые могут быть вовлечены в этиопатогенез ревматологических заболеваний, представляющие его потенциальное использование в качестве биомаркера данных патологий.

1. Homa-Mlak I, Mazurek M, Majdan A, Mlak R, Majdan M, Mełecka-Massalska T. Serum Calprotectin – a NET Product – as a Biomarker of Disease Activity in Patients with Systemic Lupus Erythematosus: A Single-Center Case-Control Study from Poland. Med Sci Monit. 2022 Jul 13; 28: e936534. DOI: 10.12659/MSM.936534

2. Barnado A, Crofford LJ, Oates JC. At the Bedside: Neutrophil extracellular traps (NETs) as targets for biomarkers and therapies in autoimmune diseases. J Leukoc Biol. 2016; 99 (2): 265–78. DOI: 10.1189/jlb.5BT0615–234R

3. Haga HJ, Brun JG, Berntzen HB, Cervera R, Khamashta M, Hughes GR. Calprotectin in patients with systemic lupus erythematosus: relation to clinical and laboratory parameters of disease activity. Lupus. 1993 Feb; 2 (1): 47–50. DOI: 10.1177/096120339300200108

4. Markowitz J, Carson WE 3rd. Review of S100A9 biology and its role in cancer. Biochim Biophys Acta. 2013 Jan; 1835 (1): 100–9. DOI: 10.1016/j.bbcan.2012.10.003

5. Horvath I, Jia X, Johansson P, Wang C, Moskalenko R, Steinau A, Forsgren L, Wågberg T, Svensson J, Zetterberg H, Morozova-Roche LA. Pro-inflammatory S100A9 Protein as a Robust Biomarker Differentiating Early Stages of Cognitive Impairment in Alzheimer's Disease. ACS Chem Neurosci. 2016 Jan 20; 7 (1): 34–9. DOI: 10.1021/acschemneuro.5b00265

6. Kruzliak P, Novák J, Novák M, Fodor GJ. Role of calprotectin in cardiometabolic diseases. Cytokine Growth Factor Rev. 2014 Feb; 25 (1): 67–75. DOI: 10.1016/j.cytogfr.2014.01.005

7. Pruenster M, Vogl T, Roth J, Sperandio M. S100A8/A9: From basic science to clinical application. Pharmacol Ther. 2016 Nov; 167: 120–131. DOI: 10.1016/j.pharmthera.2016.07.015

8. Khaki-Khatibi F, Qujeq D, Kashifard M, Moein S, Maniati M, Vaghari-Tabari M. Calprotectin in inflammatory bowel disease. Clin Chim Acta. 2020 Nov; 510: 556–565. DOI: 10.1016/j.cca.2020.08.025

9. Mariani A, Marsili M, Nozzi M, Faricelli R, Chiarelli F, Breda L. Serum calprotectin: review of its usefulness and validity in paediatric rheumatic diseases. Clin Exp Rheumatol. 2015 Jan-Feb; 33 (1): 109–14.

10. Foell D, Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum. 2004 Dec; 50 (12): 3762–71. DOI: 10.1002/art.20631

11. Korndörfer IP, Brueckner F, Skerra A. The crystal structure of the human (S100A8/ S100A9)2 heterotetramer, calprotectin, illustrates how conformational changes of interacting alpha-helices can determine specific association of two EF-hand proteins. J Mol Biol. 2007 Jul 27; 370 (5): 887–98. DOI: 10.1016/j.jmb.2007.04.065

12. Ometto F, Friso L, Astorri D, Botsios C, Raffeiner B, Punzi L, Doria A. Calprotectin in rheumatic diseases. Exp Biol Med (Maywood). 2017 Apr; 242 (8): 859–873. DOI: 10.1177/1535370216681551

13. Nukui T, Ehama R, Sakaguchi M, Sonegawa H, Katagiri C, Hibino T, Huh NH. S100A8/A9, a key mediator for positive feedback growth stimulation of normal human keratinocytes. J Cell Biochem. 2008 May 15; 104 (2): 453–64. DOI: 10.1002/jcb.21639. PMID: 18044712.

14. Sohnle PG, Hunter MJ, Hahn B, Chazin WJ. Zinc-reversible antimicrobial activity of recombinant calprotectin (migration inhibitory factor-related proteins 8 and 14). J Infect Dis. 2000 Oct; 182 (4): 1272–5. DOI: 10.1086/315810

15. Loser K, Vogl T, Voskort M, Lueken A, Kupas V, Nacken W, Klenner L, Kuhn A, Foell D, Sorokin L, Luger TA, Roth J, Beissert S. The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD 8+ T cells. Nat Med. 2010 Jun; 16 (6): 713–7. DOI: 10.1038/nm.2150

16. Lin CR, Wei TY, Tsai HY, Wu YT, Wu PY, Chen ST. Glycosylation-dependent interaction between CD 69 and S100A8/S100A9 complex is required for regulatory T-cell differentiation. FASEB J. 2015 Dec; 29 (12): 5006–17. DOI: 10.1096/fj.15–273987

17. Baillet A, Trocme C, Berthier S, Arlotto M, Grange L, Chenau J, Quétant S, Sève M, Berger F, Juvin R, Morel F, Gaudin P. Synovial fluid proteomic fingerprint: S100A8, S100A9 and S100A12 proteins discriminate rheumatoid arthritis from other inflammatory joint diseases. Rheumatology. 2010; 49: 671–82.

18. Pap T, Muller-Ladner U, Gay RE, Gay S. Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res. 2000; 2: 361–67.

19. Grevers LC, de Vries TJ, Vogl T, Abdollahi-Roodsaz S, Sloetjes AW, Leenen PJ, Roth J, Everts V, van den Berg WB, van Lent PL. S100A8 enhances osteoclastic bone resorption in vitro through activation of Toll-like receptor 4. Arthritis Rheum. 2011; 63: 1365–75.

20. Brun JG, Haga HJ, Boe E, Kallay I, Lekven C, Berntzen HB, Fagerhol MK. Calprotectin in patients with rheumatoid arthritis: relation to clinical and laboratory variables of disease activity. J Rheumatol. 1992; 19: 85962–85962.

21. Hammer HB, Haavardsholm EA, Kvien TK. Calprotectin (a major leucocyte protein) is associated with the levels of anti-CCP and rheumatoid factor in a longitudinal study of patients with very early rheumatoid arthritis. Scand J Rheumatol. 2008; 37: 179–82.

22. Tweehuysen L, den Broeder N, van Herwaarden N, Joosten LAB, van Lent PL, Vogl T, van den Hoogen FHJ, Thurlings RM, den Broeder AA. Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis. RMD Open. 2018 Apr 9; 4 (1): e000654. DOI: 10.1136/rmdopen-2018–000654

23. Brun JG, Madland TM, Gran JT, Myklebust G. A longitudinal study of calprotectin in patients with polymyalgia rheumatica or temporal arteritis: relation to disease activity. Scand J Rheumat. 2005; 34: 125–8.

24. Hsu K, Passey RJ, Endoh Y, Rahimi F, Youssef P, Yen T, Geczy CL. Regulation of S100A8 by glucocorticoids. J Immunol. 2005; 174: 2318–26.

25. Nordal HH, Brokstad KA, Solheim M, Halse AK, Kvien TK, Hammer HB. Calprotectin (S100A8/A9) has the strongest association with ultrasound-detected synovitis and predicts response to biologic treatment: results from a longitudinal study of patients with established rheumatoid arthritis. Arthritis Res Ther. 2017 Jan 12; 19 (1): 3. DOI: 10.1186/s13075-016-1201-0

26. Hammer HB, Odegard S, Fagerhol MK. et al. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. Ann Rheum Dis. 2007; 66: 1093–1097. DOI: 10.1136/ard.2006.064741

27. Vogl T, Eisenblätter M, Völler T, Zenker S, Hermann S, van Lent P, Faust A, Geyer C, Petersen B, Roebrock K, Schäfers M, Bremer C, Roth J. Alarmin S100A8/S100A9 as a biomarker for molecular imaging of local inflammatory activity. Nat Commun. 2014; 5: 4593–4593.

28. Guo Q, Zha X, Li C, Jia Y, Zhu L, Guo J, Su Y. Serum calprotectin – a promising diagnostic marker for adult-onset Still's disease. Clin Rheumatol. 2016 Jan; 35 (1): 73–9. DOI: 10.1007/s10067-015-3108-6

29. Mitrovic S, Fautrel B. New Markers for Adult-Onset Still's Disease. Joint Bone Spine. 2018 May; 85 (3): 285–293. DOI: 10.1016/j.jbspin.2017.05.011

30. De Rycke L, Baeten D, Foell D, Kruithof E, Veys EM, Roth J, De Keyser F. Differential expression and response to anti-TNFalpha treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritis. J Pathol. 2005 May; 206 (1): 17–27. DOI: 10.1002/path.1758

31. Arias JL, Funes SC, Blas R, Callegari E, Eliçabe RJ, Páez MD, Munarriz A, Pardo-Hidalgo R, Tamashiro H, Di Genaro MS. S100A8 alarmin supports IL-6 and metalloproteinase-9 production by fibroblasts in the synovial microenvironment of peripheral spondyloarthritis. Front Immunol. 2023 Jan 9; 13: 1077914. DOI: 10.3389/fimmu.2022.1077914

32. Cypers H, Varkas G, Beeckman S, Debusschere K, Vogl T, Roth J, Drennan MB, Lavric M, Foell D, Cuvelier CA, De Vos M, Delanghe J, Van den Bosch F, Elewaut D. Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis. Ann Rheum Dis. 2016 Jul; 75 (7): 1357–62. DOI: 10.1136/annrheumdis-2015-208025

33. Wang YQ, Dai XD, Ran Y, Cao Y, Lan CL, Guan JT, Liu C, Yang FM, Gan YJ, Liu BJ, Fang AW, Lin D, Gong XH, Cui RZ, Jin ZB, Qu J, Lu F, Chi ZL. Circulating S100A8/A9 Levels Reflect Intraocular Inflammation in Uveitis Patients. Ocul Immunol Inflamm. 2020; 28 (1): 133–141. DOI: 10.1080/09273948.2018.1538461

34. Turina MC, Yeremenko N, Paramarta JE, De Rycke L, Baeten D. Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis. Arthritis Res Ther. 2014 Aug 19; 16 (4): 413. DOI: 10.1186/s13075-014-0413-4

35. Benoit S, Toksoy A, Ahlmann M, Schmidt M, Sunderkötter C, Foell D, Pasparakis M, Roth J, Goebeler M. Elevated serum levels of calcium-binding S100 proteins A8 and A9 reflect disease activity and abnormal differentiation of keratinocytes in psoriasis. Br J Dermatol. 2006 Jul; 155 (1): 62–6. DOI: 10.1111/j.1365-2133.2006.07198.x

36. Kane D, Roth J, Frosch M, Vogl T, Bresnihan B, FitzGerald O. Increased perivascular synovial membrane expression of myeloid-related proteins in psoriatic arthritis. Arthritis Rheum. 2003 Jun; 48 (6): 1676–85. DOI: 10.1002/art.10988

37. Davies JC, Midgley A, Carlsson E, Donohue S, Bruce IN, Beresford MW, Hedrich CM. Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment. RMD Open. 2020 Jul; 6 (2): e001257. DOI: 10.1136/rmdopen-2020-001257

38. Gabrielsen TO, Dale I, Brandtzaeg P, Hoel PS, Fagerhol MK, Larsen TE, Thune PO. Epidermal and dermal distribution of a myelomonocytic antigen (L1) shared by epithelial cells in various inflammatory skin diseases. J Am Acad Dermatol. 1986 Aug; 15 (2 Pt 1): 173–9. DOI: 10.1016/s0190–9622(86)70152-7

39. Tydén H, Lood C, Gullstrand B, Jönsen A, Nived O, Sturfelt G, Truedsson L, Ivars F, Leanderson T, Bengtsson AA. Increased serum levels of S100A8/A9 and S100A12 are associated with cardiovascular disease in patients with inactive systemic lupus erythematosus. Rheumatology (Oxford). 2013 Nov; 52 (11): 2048–55. DOI: 10.1093/rheumatology/ket263

40. Nordal HH, Brun JG, Halse AK, Madland TM, Fagerhol MK, Jonsson R. Calprotectin (S100A8/A9), S100A12, and EDTA-resistant S100A12 complexes (ERAC) in primary Sjögren's syndrome. Scand J Rheumatol. 2014; 43 (1): 76–8. DOI: 10.3109/03009742.2013.848930

41. Balarini GM, Zandonade E, Tanure L, Ferreira GA, Sardenberg WM, Serrano ÉV, Dias CC, Navarro TP, Nordal HH, Mydel PM, Brun JG, Brokstad KA, Gerdts E, Jonsson R, Valim V. Serum calprotectin is a biomarker of carotid atherosclerosis in patients with primary Sjögren's syndrome. Clin Exp Rheumatol. 2016 Nov-Dec; 34 (6): 1006–1012.

42. Xu X, Wu WY, Tu WZ, Chu HY, Zhu XX, Liang MR, Xue Y, Wang JC, Zou HJ. Increased expression of S100A8 and S100A9 in patients with diffuse cutaneous systemic sclerosis. A correlation with organ involvement and immunological abnormalities. Clin Rheumatol. 2013 Oct; 32 (10): 1501–10. DOI: 10.1007/s10067-013-2305-4

43. Hesselstrand R, Wildt M, Bozovic G, Andersson-Sjöland A, Andréasson K, Scheja A, Westergren-Thorsson G, Bjermer L, Wuttge DM. Biomarkers from bronchoalveolar lavage fluid in systemic sclerosis patients with interstitial lung disease relate to severity of lung fibrosis. Respir Med. 2013 Jul; 107 (7): 1079–86. DOI: 10.1016/j.rmed.2013.03.015

44. Pepper RJ, Hamour S, Chavele KM, Todd SK, Rasmussen N, Flint S, Lyons PA, Smith KG, Pusey CD, Cook HT, Salama AD. Leukocyte and serum S100A8/S100A9 expression reflects disease activity in ANCA-associated vasculitis and glomerulonephritis. Kidney Int. 2013 Jun; 83 (6): 1150–8. DOI: 10.1038/ki.2013.2

45. Foell D, Hernández-Rodríguez J, Sánchez M, Vogl T, Cid MC, Roth J. Early recruitment of phagocytes contributes to the vascular inflammation of giant cell arteritis. J Pathol. 2004 Nov; 204 (3): 311–6. DOI: 10.1002/path.1660

46. Weyand CM, Ma-Krupa W, Goronzy JJ. Immunopathways in giant cell arteritis and polymyalgia rheumatica. Autoimmun Rev. 2004 Jan; 3 (1): 46–53. DOI: 10.1016/S1568–9972(03)00064-8